. 2018 Mar 7;7(4):511–522. doi: 10.1530/EC-18-0023
This work is licensed under a Table 4.
Association with subclinical hypothyroidism according to gender when population-based TSH reference range is used.
| Male total (n = 2498) | Subclinical hypothyroidism (male) | P value | Female total (n = 2303) | Subclinical hypothyroidism (female) | P value | |||
|---|---|---|---|---|---|---|---|---|
| No (n = 2440) | Yes (n = 58) | No (n = 2204) | Yes (n = 99) | |||||
| Age (years) | 0.852 | 0.009 | ||||||
| 19–29 | 526 (21.1%) | 513 (21.1%) | 13 (22.4%) | 458 (19.9%) | 444 (20.1%) | 14 (14.1%) | ||
| 30–39 | 481 (19.3%) | 472 (19.4%) | 9 (15.5%) | 401 (17.4%) | 391 (17.7%) | 10 (10.2%) | ||
| 40–49 | 492 (19.7%) | 479 (19.6%) | 13 (22.4%) | 447 (19.4%) | 425 (19.3%) | 22 (22.3%) | ||
| 50–59 | 490 (19.6%) | 477 (19.5%) | 13 (22.4%) | 507 (22.0%) | 473 (21.5%) | 34 (34.2%) | ||
| 60–69 | 461 (18.5%) | 452 (18.5%) | 9 (15.5%) | 447 (19.4%) | 431 (19.6%) | 16 (16.2%) | ||
| 70 and above | 48 (1.8%) | 47 (1.9%) | 1 (1.8%) | 43 (1.9%) | 40 (1.8%) | 3 (3.0%) | ||
| BMI (kg/m2) | 0.999 | 0.867 | ||||||
| <18.5 | 63 (2.5%) | 62 (2.4%) | 1 (2.5%) | 144 (6.3%) | 137 (6.0%) | 7 (5.2%) | ||
| ≥18.5, <23 | 824 (33.0%) | 804 (33.5%) | 20 (33.9%) | 1035 (44.9%) | 991 (43.8%) | 44 (41.7%) | ||
| ≥23, <25 | 644 (25.8%) | 629 (26.0%) | 15 (25.6%) | 497 (21.6%) | 474 (22.0%) | 23 (25.9%) | ||
| ≥25 | 967 (38.7%) | 945 (38.1%) | 22 (38.0%) | 627 (27.2%) | 602 (28.2%) | 25 (27.2%) | ||
| Region of residencea | 0.710 | 0.009 | ||||||
| Rural | 683 (27.3%) | 666 (25.9%) | 17 (28.4%) | 610 (26.5%) | 592 (26.0%) | 18 (13.8%) | ||
| Urban | 1815 (72.7%) | 1774 (74.1%) | 41 (71.6%) | 1693 (73.5%) | 1612 (74.0%) | 81 (86.2%) | ||
| Family history of thyroid disease | N/A | 0.297 | ||||||
| No | 2398 (96.0%) | 2340 (95.7%) | 58 (100.0%) | 2167 (94.1%) | 2071 (94.1%) | 96 (96.8%) | ||
| Yes | 100 (4.0%) | 100 (4.3%) | 0 (0.0%) | 136 (5.9%) | 133 (5.9%) | 3 (3.2%) | ||
| Smoking | 0.375 | 0.147 | ||||||
| No | 608 (24.3%) | 592 (24.9%) | 16 (30.9%) | 2033 (88.3%) | 1942 (88.8%) | 91 (93.6%) | ||
| Yes | 1890 (75.7%) | 1848 (75.1%) | 42 (69.1%) | 270 (11.7%) | 262 (11.2%) | 8 (6.4%) | ||
| UICRb | 0.003 | 0.033 | ||||||
| Quartile 1 | 763 (30.5%) | 756 (30.4%) | 7 (11.2%) | 463 (20.1%) | 448 (19.8%) | 15 (12.1%) | ||
| Quartile 2 | 630 (25.2%) | 617 (25.0%) | 13 (21.0%) | 566 (24.6%) | 550 (25.4%) | 16 (22.4%) | ||
| Quartile 3 | 577 (23.1%) | 562 (24.0%) | 15 (28.7%) | 602 (26.1%) | 578 (26.1%) | 24 (21.3%) | ||
| Quartile 4 | 528 (21.2%) | 505 (20.6%) | 23 (39.1%) | 672 (29.2%) | 628 (28.7%) | 44 (44.2%) | ||
| Anti-TPO Ab | <0.001 | <0.001 | ||||||
| Absence | 2396 (96.0%) | 2349 (96.3%) | 47 (82.6%) | 2076 (90.1%) | 2008 (91.5%) | 68 (66.2%) | ||
| Presence | 102 (4.0%) | 91 (3.7%) | 11 (17.4%) | 227 (9.9%) | 196 (8.5%) | 31 (33.8%) | ||
| CKD stage | 0.626 | 0.071 | ||||||
| Stage 1, 2 | 2404 (96.2%) | 2348 (96.3%) | 56 (97.4%) | 2223 (96.5%) | 2126 (95.8%) | 97 (98.8%) | ||
| Stage 3, 4, 5 | 94 (3.8%) | 92 (3.7%) | 2 (2.6%) | 80 (3.5%) | 78 (4.2%) | 2 (1.2%) | ||
*Data are presented as mean ± s.d., n (weighted %), statistics were carried out using Rao-Scott Chi-square test; aclassification of the area of residence is classified according to the administrative division of Korea; biodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: <Q1 (141.53203438), quartile 2: ≥Q1 and <Q2 (281.81447737), quartile 3: ≥Q2 and <Q3 (664.64655625), quartile 4: ≥Q3.
N/A, not available.